Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | NOS3 | P29474 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 2/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Picolamine SCHEMBL29071785 | 0.91 | MEN1 (0.53) | SLC6A4NOS3NOS1NOS2HTR1A | |
| SCHEMBL7489582 | 0.86 | SLC6A4 (0.57) | SLC6A4HTR1ADRD2MEN1HTT | |
| SCHEMBL1196687 | 0.83 | CCR5 (0.64) | SLC6A4CCR5KMT2AMRGPRX4PTGER1 | |
| Hydrochloric Acid SCHEMBL6214742 | 0.81 | CCR5 (0.62) | SLC6A4CCR5KMT2AMRGPRX4PTGER1 | |
| Ammonia Solution, Strong SCHEMBL29071779 | 0.81 | MRGPRX4 (0.53) | SLC6A4CCR5HTTMRGPRX4PTGER1 | |
| Hydrochloric Acid SCHEMBL6213322 | 0.80 | MRGPRX4 (0.62) | SLC6A4CCR5MRGPRX4 | |
| SCHEMBL31252511 | 0.79 | MEN1 (0.75) | MEN1HTTKMT2APTGER1LRRK2 | |
| Hydrochloric Acid SCHEMBL6215773 | 0.78 | CCR5 (0.75) | SLC6A4CCR5MRGPRX4PTGER1 | |
| SCHEMBL6216769 | 0.78 | GRM5 (0.54) | SLC6A4HTR1ADRD2MEN1HTT | |
| SCHEMBL30335622 | 0.77 | SLC6A4 (0.56) | SLC6A4HTR1ADRD2MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | SLC6A4 1655/4885NOS3 68/4885NOS1 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.